Andreas Brückner

Quantitative Safety & Epidemiology, Patient Safety & Pharmacovigilance, Development, Novartis Pharma AG, Basel, Switzerland, Switzerland

Poster(s):

• (028) Results from an analysis of data from the US SEER registries to estimate the prevalence of gastroenteropancreatic neuroendocrine tumors in the US, in the context of limited available evidence for regulatory discussions
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST